The global combination product market has seen a tremendous amount of growth, driven primarily by the rise in chronic disease indications, the demand for self-administered therapies, minimally invasive procedures and technology advancements.
However, there are many challenges that need to be navigated as you consider the transition from a vial system to a needle-based combination product, including stringent government regulations, a complex supply chain and the need for better patient outcomes.
This webinar will focus on three big challenges pharmaceutical companies face as they consider the life cycle management strategy and transition to a combination product.
Key points to be addressed include:
• Steps to de-risking drug and device integration
• Strategies to de-risk the combination product development process and use testing
• Data decisions needed to support device reliability and robustness
Key Learning Objectives
- Steps to de-risking drug and device integration
- Strategies to de-risk the combination product development process and use testing
- Better understanding of data needed to support device reliability and robustness
